

- a) a protein which has at least one catalytic domain and at least one binding domain,
 - b) a marker substrate which binds to the catalytic domain and is converted by the protein, and
 - c) a substrate which can bind to the catalytic domain and to the binding domain.
5. 4-(Diphenylmethylene)-1-[4-(p-fluorophenyl)-4-phenyl-3-butenyl]piperidine.
 6. A pharmaceutical composition comprising 4-(diphenyl-methylene)-1-[4-(p-fluorophenyl)-4-phenyl-3-butenyl]piperidine, and at least one pharmaceutically suitable and physiologically tolerated carrier, additive or excipient.
 7. A pharmaceutical composition according to claim 6 further comprising other active ingredients.
 8. A method of treating a disorder comprising administering to a patient in need thereof an effective amount of a substance selected from 4-(diphenylmethylene)-1-[4-(p-fluorophenyl)-4-phenyl-3-butenyl]- piperidine, protamine sulfate, oligosaccharides or tetrasaccharides, wherein said oligosaccharides or tetrasaccharides are obtained from heparin degradation.,.
 9. A method according to claim 8 wherein the disorder involves increased activity of matrix-degrading enzymes.
 10. A method according to claim 9 wherein the matrix-degrading enzymes are selected from: collagenases, metalloproteinases or aggrecanase.

11. A method according to claim 9 wherein the disorder is a degenerative joint disorder.
12. A method according to claim 11 wherein the degenerative joint disorder is selected from:
osteoarthroses,
spondyloses,
chondrolysis after joint trauma or
prolonged immobilization of joints after meniscus or patella injuries or
tearing of ligaments.
13. A method according to claim 9 wherein the disorder is a disorder of the connective tissue.
14. A method according to claim 13 wherein the disorder of the connective tissue is selected from: collagenoses, periodontal disorders, wound-healing disturbances or chronic disorders of the locomotor apparatus
15. A method according to claim 14 wherein the chronic disorder of the locomotor apparatus is selected from: inflammatory, immunologically or metabolically caused acute or chronic arthritis, arthropathies, myalgias or disorders of bone metabolism.
16. A method according to claim 8 for the treatment of ulceration, arteriosclerosis, stenoses, inflammations, cancers, formation of tumor metastases, cachexia, anorexia or septic shock.
17. A substance which is determined to be an inhibitor or ligand by the method as claimed in any one of claims 1-3.